Indore-based pharma maker of generic formulations, nutraceuticals and injectables, manufactured at its Pithampur plant.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 78 | 79 | 86 | 94 | 94 | 94 | 94 | 94 |
| Reserves | 68 | 109 | 136 | 162 | 192 | 246 | 282 | 318 |
| Borrowings | 2 | 62 | 58 | 83 | 72 | 4 | 0 | 1 |
| Other Liabilities | 33 | 42 | 28 | 38 | 33 | 66 | 74 | 116 |
| Total Liabilities | 181 | 292 | 308 | 377 | 392 | 410 | 451 | 529 |
| AssetsFixed Assets | 93 | 91 | 94 | 91 | 120 | 125 | 124 | 184 |
| CWIP | 0 | 0 | 6 | 26 | 0 | 0 | 8 | 0 |
| Investments | 1 | 11 | 43 | 64 | 66 | 93 | 148 | 109 |
| Other Assets | 87 | 189 | 165 | 196 | 206 | 192 | 171 | 237 |
| Total Assets | 181 | 292 | 308 | 377 | 392 | 410 | 451 | 529 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | 6 | -2 | 16 | 10 | -6 | 23 | 58 |
| Cash from Investing | 2 | 2 | -75 | -27 | -45 | 84 | -18 | -51 |
| Cash from Financing | 0 | -7 | 72 | 8 | 35 | -15 | -68 | -3 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 10 | 4 | -5 | 5 | -10 | -14 | 13 | 47 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (33.6×) and current (19.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 49.6% growth and a 20× exit, ₹14 only delivers your return if you pay ₹54. The price is currently baking in 17% growth.
EPS grows 49.6%/yr for 5 years, then fades to 6% over 2, exits at 20×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 49.6% | 1.06 |
| FY28 | 49.6% | 1.59 |
| FY29 | 49.6% | 2.38 |
| FY30 | 49.6% | 3.56 |
| FY31 | 49.6% | 5.32 |
| FY32 | 27.8% ·fade | 6.80 |
| FY33 | 6.0% ·fade | 7.21 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.